The announcement of NKGen Biotech's publication at a prestigious conference like ASCO underscores the company's advancements in cancer treatment, which could enhance its reputation and investor interest. Given the high relevance of this news to NKGen Biotech and its direct impact on the company's perception in the biotech and investment communities, it is likely to have a positive short-term impact on NKGN's stock price. The confidence level reflects the typical market response to such announcements, although actual impact can vary based on broader market conditions and subsequent developments in the company's research.